Guide study

Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

G. Schernthaner, A. Grimaldi, U. Di Mario, J. Drzewoski, P. Kempler, M. Kvapil, A. Novials, R. Rottiers, G. E H M Rutten, K. M. Shaw

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Background: Progressive β-cell failure is a characteristic feature of type 2 diabetes; consequently, β-cell secretagogues are useful for achieving sufficient glycaemic control. The European GUIDE study is the first large-scale head-to-head comparison of two sulphonylureas designed for once-daily administration used under conditions of everyday clinical practice. Design: Eight hundred and forty-five type 2 diabetic patients were randomized to either gliclazide modified release (MR) 30-120 mg daily or glimepiride 1-6 mg daily as monotherapy or in combination with their current treatment (metformin or an α-glucosidase inhibitor) according to a double-blind, 27-week, parallel-group design. Efficacy was evaluated by HbA1c and safety by hypoglycaemic episodes using the European Agency definition. Results: HbA 1c decreased similarly in both groups from 8-4% to 7-2% on gliclazide MR and from 8.2% to 7.2% on glimepiride. Approximately 50% of the patients achieved HbA1c levels less than 7%, and 25% less than 6.5%. The mean difference between groups of the final HbA1c was -0.06% (noninferiority test P <0.0001). No hypoglycaemia requiring external assistance occurred. Hypoglycaemia with blood glucose level <3 mmol L-1 occurred significantly less frequently (P = 0.003) with gliclazide MR (3.7% of patients) compared with glimepiride (8.9% of patients). The distribution of the sulphonylurea doses was similar in both groups. Conclusions: This study provides new insights into therapeutic strategies using sulphonylureas. It shows that gliclazide MR is at least as effective as glimepiride, either as monotherapy or in combination. The safety of gliclazide MR was significantly better, demonstrating approximately 50% fewer confirmed hypoglycaemic episodes in comparison with glimepiride.

Original languageEnglish
Pages (from-to)535-542
Number of pages8
JournalEuropean Journal of Clinical Investigation
Volume34
Issue number8
DOIs
Publication statusPublished - Aug 2004

Fingerprint

glimepiride
Gliclazide
Double-Blind Method
Hypoglycemia
Hypoglycemic Agents
Glucosidases
Safety
Metformin
Medical problems
Type 2 Diabetes Mellitus
Blood Glucose

Keywords

  • Glucose control
  • HbA
  • Hypoglycaemia
  • Sulphonylureas
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Guide study : Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. / Schernthaner, G.; Grimaldi, A.; Di Mario, U.; Drzewoski, J.; Kempler, P.; Kvapil, M.; Novials, A.; Rottiers, R.; Rutten, G. E H M; Shaw, K. M.

In: European Journal of Clinical Investigation, Vol. 34, No. 8, 08.2004, p. 535-542.

Research output: Contribution to journalArticle

Schernthaner, G, Grimaldi, A, Di Mario, U, Drzewoski, J, Kempler, P, Kvapil, M, Novials, A, Rottiers, R, Rutten, GEHM & Shaw, KM 2004, 'Guide study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients', European Journal of Clinical Investigation, vol. 34, no. 8, pp. 535-542. https://doi.org/10.1111/j.1365-2362.2004.01381.x
Schernthaner, G. ; Grimaldi, A. ; Di Mario, U. ; Drzewoski, J. ; Kempler, P. ; Kvapil, M. ; Novials, A. ; Rottiers, R. ; Rutten, G. E H M ; Shaw, K. M. / Guide study : Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. In: European Journal of Clinical Investigation. 2004 ; Vol. 34, No. 8. pp. 535-542.
@article{5bc45ec50a0141bd88ac469a3b1ef8ac,
title = "Guide study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients",
abstract = "Background: Progressive β-cell failure is a characteristic feature of type 2 diabetes; consequently, β-cell secretagogues are useful for achieving sufficient glycaemic control. The European GUIDE study is the first large-scale head-to-head comparison of two sulphonylureas designed for once-daily administration used under conditions of everyday clinical practice. Design: Eight hundred and forty-five type 2 diabetic patients were randomized to either gliclazide modified release (MR) 30-120 mg daily or glimepiride 1-6 mg daily as monotherapy or in combination with their current treatment (metformin or an α-glucosidase inhibitor) according to a double-blind, 27-week, parallel-group design. Efficacy was evaluated by HbA1c and safety by hypoglycaemic episodes using the European Agency definition. Results: HbA 1c decreased similarly in both groups from 8-4{\%} to 7-2{\%} on gliclazide MR and from 8.2{\%} to 7.2{\%} on glimepiride. Approximately 50{\%} of the patients achieved HbA1c levels less than 7{\%}, and 25{\%} less than 6.5{\%}. The mean difference between groups of the final HbA1c was -0.06{\%} (noninferiority test P <0.0001). No hypoglycaemia requiring external assistance occurred. Hypoglycaemia with blood glucose level <3 mmol L-1 occurred significantly less frequently (P = 0.003) with gliclazide MR (3.7{\%} of patients) compared with glimepiride (8.9{\%} of patients). The distribution of the sulphonylurea doses was similar in both groups. Conclusions: This study provides new insights into therapeutic strategies using sulphonylureas. It shows that gliclazide MR is at least as effective as glimepiride, either as monotherapy or in combination. The safety of gliclazide MR was significantly better, demonstrating approximately 50{\%} fewer confirmed hypoglycaemic episodes in comparison with glimepiride.",
keywords = "Glucose control, HbA, Hypoglycaemia, Sulphonylureas, Type 2 diabetes",
author = "G. Schernthaner and A. Grimaldi and {Di Mario}, U. and J. Drzewoski and P. Kempler and M. Kvapil and A. Novials and R. Rottiers and Rutten, {G. E H M} and Shaw, {K. M.}",
year = "2004",
month = "8",
doi = "10.1111/j.1365-2362.2004.01381.x",
language = "English",
volume = "34",
pages = "535--542",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Guide study

T2 - Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

AU - Schernthaner, G.

AU - Grimaldi, A.

AU - Di Mario, U.

AU - Drzewoski, J.

AU - Kempler, P.

AU - Kvapil, M.

AU - Novials, A.

AU - Rottiers, R.

AU - Rutten, G. E H M

AU - Shaw, K. M.

PY - 2004/8

Y1 - 2004/8

N2 - Background: Progressive β-cell failure is a characteristic feature of type 2 diabetes; consequently, β-cell secretagogues are useful for achieving sufficient glycaemic control. The European GUIDE study is the first large-scale head-to-head comparison of two sulphonylureas designed for once-daily administration used under conditions of everyday clinical practice. Design: Eight hundred and forty-five type 2 diabetic patients were randomized to either gliclazide modified release (MR) 30-120 mg daily or glimepiride 1-6 mg daily as monotherapy or in combination with their current treatment (metformin or an α-glucosidase inhibitor) according to a double-blind, 27-week, parallel-group design. Efficacy was evaluated by HbA1c and safety by hypoglycaemic episodes using the European Agency definition. Results: HbA 1c decreased similarly in both groups from 8-4% to 7-2% on gliclazide MR and from 8.2% to 7.2% on glimepiride. Approximately 50% of the patients achieved HbA1c levels less than 7%, and 25% less than 6.5%. The mean difference between groups of the final HbA1c was -0.06% (noninferiority test P <0.0001). No hypoglycaemia requiring external assistance occurred. Hypoglycaemia with blood glucose level <3 mmol L-1 occurred significantly less frequently (P = 0.003) with gliclazide MR (3.7% of patients) compared with glimepiride (8.9% of patients). The distribution of the sulphonylurea doses was similar in both groups. Conclusions: This study provides new insights into therapeutic strategies using sulphonylureas. It shows that gliclazide MR is at least as effective as glimepiride, either as monotherapy or in combination. The safety of gliclazide MR was significantly better, demonstrating approximately 50% fewer confirmed hypoglycaemic episodes in comparison with glimepiride.

AB - Background: Progressive β-cell failure is a characteristic feature of type 2 diabetes; consequently, β-cell secretagogues are useful for achieving sufficient glycaemic control. The European GUIDE study is the first large-scale head-to-head comparison of two sulphonylureas designed for once-daily administration used under conditions of everyday clinical practice. Design: Eight hundred and forty-five type 2 diabetic patients were randomized to either gliclazide modified release (MR) 30-120 mg daily or glimepiride 1-6 mg daily as monotherapy or in combination with their current treatment (metformin or an α-glucosidase inhibitor) according to a double-blind, 27-week, parallel-group design. Efficacy was evaluated by HbA1c and safety by hypoglycaemic episodes using the European Agency definition. Results: HbA 1c decreased similarly in both groups from 8-4% to 7-2% on gliclazide MR and from 8.2% to 7.2% on glimepiride. Approximately 50% of the patients achieved HbA1c levels less than 7%, and 25% less than 6.5%. The mean difference between groups of the final HbA1c was -0.06% (noninferiority test P <0.0001). No hypoglycaemia requiring external assistance occurred. Hypoglycaemia with blood glucose level <3 mmol L-1 occurred significantly less frequently (P = 0.003) with gliclazide MR (3.7% of patients) compared with glimepiride (8.9% of patients). The distribution of the sulphonylurea doses was similar in both groups. Conclusions: This study provides new insights into therapeutic strategies using sulphonylureas. It shows that gliclazide MR is at least as effective as glimepiride, either as monotherapy or in combination. The safety of gliclazide MR was significantly better, demonstrating approximately 50% fewer confirmed hypoglycaemic episodes in comparison with glimepiride.

KW - Glucose control

KW - HbA

KW - Hypoglycaemia

KW - Sulphonylureas

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=4344693381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344693381&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2362.2004.01381.x

DO - 10.1111/j.1365-2362.2004.01381.x

M3 - Article

VL - 34

SP - 535

EP - 542

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 8

ER -